Kingsview Wealth Management recently bought a new stake in Vertex Pharmaceuticals. They snagged 545 shares, valued around ...

For the third summer in a row, Vertex Pharmaceuticals brought its commitment to community and STEM education to life through ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $476.95, moving +1.45% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.78% ...

Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...

Vertex Pharmaceuticals' new therapy, zimislecel, has potential to be a "functional cure," experts say. A new stem cell ...

Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

NRI PULSE STAFF REPORT The 2025 edition of TIME100 Most Influential Companies honors leaders and innovators who are ...

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...